Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs BEAM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BEAM Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–4 Matrix Metrics)

BEAM Overall Winner 6-Pillar Tally: NTLA 1 – 5 BEAM Matrix Metrics: NTLA 4 – 4 BEAM

As of Nov 16, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. BEAM 45.9/100 HOLD), BEAM captures the overall institutional head-to-head verdict (4–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-267.7% vs. -826.0% operating margin) and revenue trajectory (-96.8% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs BEAM
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
BEAM NASDAQ Head-to-Head Winner
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$21.29
-6.75% 1D
Market Cap $2.4B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 52.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $25.54 · SMA50: $24.99

6-Pillar Scorecard Institutional Category Breakdown (NTLA 1 – 5 BEAM)

Columns: Metric · NTLA · BEAM
1. Valuation Multiples BEAM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 16.8x
2. Growth & Scale BEAM
Revenue Growth (YoY) -48.0% -96.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $147M
Market Cap $1.5B $2.4B
3. Profitability & Quality BEAM
Gross Margin N/A N/A
Operating Margin -826.0% -267.7%
Net Profit Margin 0.0% -73.9%
Return on Equity (ROE) -62.6% -11.3%
4. Balance Sheet & Cash Flow BEAM
Cash Generation (TTM) -$358M -$398M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $31M Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BEAM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 66.0% (42nd %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (4) vs BEAM (4)
Institutional Metric NTLA BEAM Criterion Row Edge
Market Capitalization
Scale
$1.5B $2.4B Larger Scale BEAM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% -96.8% Higher Growth NTLA
Operating Margin (TTM)
Profitability
-826.0% -267.7% Higher Margin BEAM
Net Profit Margin
Profitability
0.0% -73.9% Higher Margin NTLA
Return on Equity (ROE)
Capital Efficiency
-62.6% -11.3% Higher ROE BEAM
52-Week Range Position
Momentum
20% ($8–$18) 6% ($20–$38) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 2.24β · 86% Vol Lower Realized Risk BEAM
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $147M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$398M ($31M Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BEAM +3.14 pp
NTLA: -12.43% · BEAM: -9.29%
3M Horizon NTLA +6.08 pp
NTLA: -13.79% · BEAM: -19.87%
6M Horizon BEAM +0.61 pp
NTLA: -21.2% · BEAM: -20.59%
1Y Horizon NTLA +17.05 pp
NTLA: +15.34% · BEAM: -1.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue BEAM Revenue NTLA Op. Margin BEAM Op. Margin Margin Leader
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M $0M -246.8% -417522.2% NTLA
FY2020 $60M $0M -235.5% -553166.7% NTLA
FY2021 $30M $50M -810.4% -757.0% BEAM
FY2022 $50M $60M -879.0% -555.6% BEAM
FY2023 $40M $380M -1420.5% -46.7% BEAM
FY2024 $60M $60M -923.1% -654.3% BEAM
FY2025 $70M $140M -651.7% -274.6% BEAM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BEAM BREAKDOWN
103d in phase · OBV DISTRIBUTION
Current IV 66.0%
IV Percentile 42nd %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs BEAM Key Questions & Quantitative Answers

As of Nov 16, 2026, Beam Therapeutics Inc. (BEAM) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas BEAM carries 45.9/100 (HOLD) at $21.29 (N/M Forward P/E, -267.7% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. BEAM 45.9/100 HOLD), BEAM captures the overall institutional head-to-head verdict (4–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-267.7% vs. -826.0% operating margin) and revenue trajectory (-96.8% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BEAM leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.

BEAM screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus BEAM (-11.3% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.